AUTONOMIC NERVOUS SYSTEM



The Autonomic Nervous System (ANS) is under control of the Central Nervous System (CNS)







Autonomic Nervous System fibers



Key:

Preganglionic axons ---= Postganglionic axons == Myelination == Preganglionic axons ---= Postganglionic axons (sympathetic) (parasympathetic) (parasympathetic)

PNS vs SNS

The parasympathetic nervous system (PNS) controls homeostasis of the body at rest and is responsible for the "rest and digest" function

The sympathetic nervous system (SNS) controls the body's responses to a perceived threat and is responsible for the "fight or flight" response

PARASYMPATHETIC DIVISION



"rest and digest" functions:

Eyes: Accommodation for near vision Miosis

Bronchi: Constriction Increased secretion



Saliva: Copious, liquid

Heart: Decreased rate Decreased blood pressure

Gastro-intestinal tract:

Increased secretion Increased peristalsis Decreased sphincter tone

Bladder:

Increased detrusor tone Decreased sphincter tone



SNC: Increased drive and alertness

> Saliva: Little, viscous

> > Bronchi: Dilatation

"Fight or flight" functions

Liver: Glycogenolysis Glucose release

Gastrointestinal tract: Decreased peristalsis Increased sphincter tone Decreased blood flow



Eyes: Pupillary dilation

Heart:

Increased rate Increased force Increased blood pressure

Fat tissue: Lipolysis Fatty acids liberation

Bladder: Decreased detrusor tone Increased sphincter tone

Skeletal muscle: Increased blood flow Increased glycogenolysis

The circular and radial muscles control the size of the pupil



Miosis

Midriasis



The ciliary muscles control the shape of the lens



Parasympathetic system: Detrusor muscle contracts

Sympathetic system: Detrusor muscle relax Internal urethral sphincter contracts



Nature Reviews | Neurosci

Intestinal tract



Sympathetic system: Decreased peristalsis Increased sphincter tone Parasympathetic system: Increased peristalsis Decreased sphincter tone



CHOLINERGIC TRANSMISSION ACETYLCHOLINE SYNTHESIS AND DEGRADATION



ACETYLCHOLINE RECEPTORS (Dale, 1914)

NICOTINIC ionotropic



MUSCARINIC metabotropic





NICOTINIC RECEPTORS



| SUBTYPE | MAIN LOCALIZATION | MEMBRANE RESPONSE |
|---|---|----------------------|
| Muscle type (alpha1)2-beta1- delta- epsilon | Skeletal neuromuscular junction (mainly post-synaptic) | Excitatory |
| Ganglion type (alpha3)2-(beta2)3 | Autonomic ganglia (mainly post-synaptic) | Excitatory |
| CNS type (alpha4)2-(beta2)3 (alpha7)5 | Many brain regions: pre- and post-synaptic | Excitatory |

NICOTINIC RECEPTORS

| SUBTYPE | AGONISTS | CLINICAL USE | |
|---|---|---|--|
| Muscle type | Acetylcholine | None | |
| (alpha1)2- | Carbachol | None | |
| beta1-delta- | Succinylcholine | Paralysis during | |
| epsilon | Suxamethonium | anaesthesia (short acting) | |
| Ganglion type (alpha3)2- (beta2)3 | Acetylcholine Carbachol Nicotine Epibatidine | None None Smoke cessation None | |
| CNS type | Nicotine | None | |
| (alpha4)2- | Epibatidine | None | |
| (beta2)3 | Acetylcholine | None | |
| (alpha7)5 | Varenicline | Smoke cessation | |

NICOTINIC RECEPTORS

| SUBTYPE | ANTAGONISTS | CLINICAL USE | |
|--|--|--|--|
| Muscle type (alpha1)2- beta1-delta- epsilon | Tubocurarine Pancuronium Atracurium Vecuronium | Paralysis during anaesthesia | |
| Ganglion type (alpha3)2- (beta2)3 | Mecamylamine Trimetaphan Hexamethonium | Obsolete anti-hypertensive drug | |
| CNS type (alpha4)2- (beta2)3 | Mecamylamine Methylaconitine Alpha-bungarotoxin Alpha-conotoxin | Crosses the BBB (antagonizes nicotine CNS effects) | |
| (alpha/)5 | | | |



| MUSCARINIC RECEPTOR | | | |
|-------------------------------------|---|---|--|
| SUBTYPE | MAIN LOCATION | FUNCTIONAL RESPONSE | |
| M1 ("neural) | Cerebral cortex Autonomic ganglia | CNS excitation Gastric secretion | |
| M2 ("cardiac") | Heart: atria CNS | Cardiac inhibition (bradicardia) Neural inhibition | |
| M3 | Exocrine glands: gastric, salivary_etc | Gastric, salivary secretion | |
| ("Glandular - Smooth muscle") | Smooth muscle: GI tract, eye, airways, bladder Blood vessel (endothelium) | Contraction, ocular accomodation Vasodilatation (NO-mediated) | |
| M4 | CNS | Enhanced locomotion | |
| M5 | CNS (very localized expression) | Not known | |

| MUSCARINIC RECEPTOR | | | |
|---|--|--|--|
| SUBTYPE | AGONISTS | CLINICAL USE | |
| M1 ("neural) | NON-SELECTIVE: Acetylcholine Carbachol Pilocarpine Bethanechol | - - Glaucoma Treatment of bladder and gastrointestinal hypotonia | |
| M2 ("cardiac") | Not known | | |
| M3 ("Glandular - Smooth muscle") | SELECTIVE: Cevimeline | Sjögren'syndrome (to increase salivary and lacrimal secretion) | |
| M4 | Not known | Not known | |
| M5 | Not known | Not known | |

| MUSCARINIC RECEPTOR | | | |
|-------------------------------|---|--|--|
| SUBTYPE | ANTAGONISTS | CLINICAL USE | |
| M1 ("neural) | NON-SELECTIVE: Atropine Oxibutynin Ipatropium SELECTIVE: Pirenzepine | Ophthalmic (midriasis and paralisis of accomodation) Prevention of motion sickness COPD and Asthma Anaesthetic premedication | |
| M2 ("cardiac") | Gallamine | | |
| M3 ("Glandular - Smooth | SELECTIVE Darifenacin | Urinary incontinence | |
| M4 | Not known | | |
| M5 | Not known | | |

Antimuscarinic drug side effects: dry mouth and skin (dry as a bone), cyclopegia (blind as a bat), bradicardia, urinary retention (full as s flask), constipation, restlessness, irritability (mad as a hatter)

ADRENERGIC TRANSMISSION NORADRENALINE SYNTHESIS AND DEGRADATION



ADRENERGIC RECEPTOR CLASSIFICATION

Epinephrine and Norepinephrine show relatively little receptor **selectivity**

The main pharmacological classification into alfa (α) and beta (β) was originally based on order of potency of agonists:

alfa (α): Epinephrine = NE > dopamine > isoproterenol beta (β): Isoproterenol = Epineprine > NE > dopamine

| | α1 | α2 | β1 | β ₂ | DA |
|----------------|-----|-----|-----|----------------|-----|
| Norepinephrine | +++ | +++ | + | - | - |
| Epinephrine | +++ | ++ | +++ | ++ | - |
| Dopamine | ++ | + | ++ | +++ | +++ |
| Dobutamine | + | - | +++ | + | - |
| Isoproterenol | - | - | ++ | ++ | - |

AlphaADRENERGIC RECEPTORS

alpha (α)1: Gq/11



alpha (α)2: Gi/o

- N or P/Q-type Ca⁺⁺ channel mediated release
- Gβγ mediated inhibition via
 - either inhibition of N or P/Q type Ca⁺⁺ channel
 - or activation of K⁺ channel
 - or inhibition of key synaptic proteins



Alpha ADRENERGIC RECEPTOR

| SUBTYPE | MAIN LOCATION | FUNCTIONAL RESPONSE |
|---------|--|--|
| | Blood vessels | Contraction |
| Alpha 1 | GI tract GI sphincters Bladder sphincter Iris | Relaxation Contraction Contraction Contraction (midriasis) |
| Alpha 2 | Presynaptic brain stem Presynaptic nerve terminals | Inhibition of sympathetic outflow Decreased release of neurotransmitters |

| Alpha ADRENERGIC RECEPTOR | | | |
|---------------------------|--|---|--|
| SUBTYPE | AGONISTS | CLINICAL USES | |
| Alpha 1 | Phenylephrine Methoxamine | Nasal decongestion | |
| Alpha 2 | Clonidine | Hypertension | |
| | ANTAGONISTS | CLINICAL USES | |
| | | | |
| Alpha 1 | Prazosin Doxazocin | Hypertension | |
| Alpha 1 | Prazosin Doxazocin Tamsulosin | Hypertension Benign prostatic hypertophy | |

| Beta ADRENERGIC RECEPTOR | | EXTRACELLULAR FLUID | |
|--------------------------|--|---|--|
| SUBTYPE | MAIN LOCATION | FUNCTIONAL RESPONSE | Epinephrine |
| Beta 1 | Heart Kidney (iuxtaolomerular | Increase rate and force of contraction Renine release | β-adrenergic receptor Active G protein α |
| Beta 2 | Smooth muscle: bronchi, blood vessel ciliary, GI tract, bladder detrusor | Relax | CAMP |
| | Skeletal muscle | Increase mass, tremor Glycogenolysis | Responses of target cell: Smooth muscle relaxation, vasodilation |
| Beta 3 | Fat tissue | Lipolysis, thermogenesis | beta (β) 1, 2, 3 : Gs |



PHOSPHORYLATION OF L-TYPE CALCIUM CHANNELS INCREASE OF CICR (CALCIUM INDUCED CALCIUM RELEASE) ----> POSITIVE INOTROPIC EFFECT

VASAL SMOOTH MUSCLE



INHIBITION OF MLCK (MYOSIN LIGHT CHAIN KINASE) -----> VASODILATATION

| Beta ADRENERGIC RECEPTOR | | | |
|--------------------------|---|--------------------------------|--|
| SUBTYPE | AGONISTS | CLINICAL USES | |
| Beta 1 | Dobutamine | Cardiogenic shock | |
| Beta 2 | Salbutamol Terbutaline Formoterol | Asthma | |
| Beta 3 | Mirabegron | Symptoms of overactive bladder | |

| SUBTYPE | ANTAGONISTS | CLINICAL USES |
|---------|--|---|
| Beta 1 | Propranolol Alprenolol Metoprolol Nevibolol | Angina pectoris Hypertension Cardiac dysrhytmias (Anxiety, tremor) |
| Beta 2 | Butoxamine | None |
| Beta 3 | None | |



Effect of intravenous infusion of Norepinephrine, Epinephrine or Isoproterenol in human beings



Effect of intravenous infusion of Norepinephrine, Epinephrine or Isoproterenol in human beings

BAROCEPTOR, CHEMOCEPTOR AND CARDIOVASCULAR REGULATION

